Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling

Anne Louise Hansen
Aarhus University

Et al.

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Immune System Diseases Commons, and the Immunology and Infectious Disease Commons

Repository Citation

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling


*Department of Biomedicine, Aarhus University, 8000 Aarhus C, Denmark; bDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15213; cDepartment of Pharmaceutical Chemistry, Goethe University, 60438 Frankfurt am Main, Germany; dDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, 113-0033 Tokyo, Japan; eDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01655; fDepartment of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany; gLady Davis Institute, Department of Medicine, McGill University, H3T 1Z2 Montreal, QC, Canada; hTranslational Autoinflammatory Disease Studies Unit, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20850; iDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110; jDepartment of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110; kDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110; lMedical Research Council (MRC) Human Immunology Unit, University of Oxford, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, OX3 9DS Oxford, United Kingdom; mJapan Agency for Medical Research and Development (AMED)-Core Research Division Infectious Diseases and Immunology, University of Medicine and Dentistry of Tokushima, Japan; nLaboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, 980-8587 Miyagi, Japan; and AMED-Precurory Research for Innovative Medical Care (PRIME), Japan Agency for Medical Research and Development, 100-0004 Tokyo, Japan

Edited by Daniel B. Stetson, University of Washington, Seattle, WA, and accepted by Editorial Board Member Ruslan Medzhitov July 3, 2018 (received for review April 11, 2018)

The adaptor molecule stimulator of IFN genes (STING) is central to production of type I IFNs in response to infection with DNA viruses and to presence of host DNA in the cytosol. Excessive release of type I IFNs through STING-dependent mechanisms has emerged as a central driver of several interferonopathies, including systemic lupus erythematosus (SLE), Aicardi–Goutières syndrome (AGS), and stimulator of IFN genes-associated vasculopathy with onset in infancy (SAVI). The involvement of STING in these diseases points to an unmet need for the development of agents that inhibit STING signaling. Here, we report that endogenously formed nitro-fatty acids can covalently modify STING by nitro-alkylation. These nitro-alkylations inhibit STING palmitoylation, STING signaling, and subsequently, the release of type I IFN in both human and murine cells. Furthermore, treatment with nitro-fatty acids was sufficient to inhibit production of type I IFN in fibroblasts derived from SAVI patients with a gain-of-function mutation in STING. In conclusion, we have identified nitro-fatty acids as endogenously formed inhibitors of STING signaling and propose for these lipids to be considered in the treatment of STING-dependent inflammatory diseases.

Significance

Several chronic inflammatory conditions have recently been shown to depend on abnormally high activity of the signaling protein stimulator of IFN genes (STING). These conditions include examples from systemic lupus erythematosus, Aicardi–Goutières syndrome, and STING-associated vasculopathy with onset in infancy. The involvement of STING in these diseases points to an unmet demand to identify inhibitors of STING signaling, which could form the basis of anti-STING therapeutics. With this report, we identify distinct endogenously formed lipid species as potent inhibitors of STING signaling—and propose that these lipids could have pharmaceutical potential for treatment of STING-dependent inflammatory diseases.


Conflict of interest statement: F.J.S. declares financial interest in Complexa Inc.

This article is in PNAS Direct Submission. D.B.S. is a guest editor invited by the Editorial Board.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1To whom correspondence should be addressed. Email: holm@biomed.au.dk.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1806239115/-/DCSupplemental.

Published online July 30, 2018.
and a relatively large cytosolic C-terminal domain (amino acids 138–379). The structure of the cytosolic domain has been solved by X-ray crystallography and has been identified as the site of cGAMP binding and TBK1 and IRF3 phosphorylation (14–17). By contrast, it is largely unknown how the N-terminal region and its four predicted transmembrane regions contribute to STING function. However, a recent study has identified N-terminal cysteine residues at positions 88 and 91 as targets of palmitoylation in response to stimulation with cytosolic dsDNA. Palmitoylation at Cys88/91 was important for STING-dependent phosphorylation of TBK1 in the trans-Golgi network (TGN) and thus, central to STING-dependent induction of type I IFNs (18). It is currently unknown if palmitoylation at these cysteine residues can be targeted to inhibit STING signaling.

Recently, nitro-fatty acids (NO$_2$-FAs) have emerged as a group of bioactive lipids with antiinflammatory properties (19). At this stage, only a limited number of NO$_2$-FAs have been identified, and their importance in immune regulation during infection is poorly understood. Endogenous formation of NO$_2$-FAs is the result of nitrogen dioxide (NO$_2$) addition preferentially to unsaturated fatty acids, such as conjugated linoleic acid (cLA) and oleic acid (OA), to form nitro-conjugated linoleic acid (NO$_2$-cLA) and nitro-oleic acid (NO$_2$-OA), respectively (20). During inflammation, formation of NO$_2$ depends on the presence of inducible nitric oxide synthase (iNOS)-derived NO, its autooxidation, or its reaction with oxygen species, including the NADPH oxidase (NOX)-derived superoxide anion O$_2^•−$ (21). The NO$_2$ reacts with lipid species to form NO$_2$-FAs (22) (Fig. 1A).

Formed NO$_2$-FAs have the ability to modify target proteins posttranslationally (S-nitro-alkylation) through Michael addition reactions. The thiol group on cysteine residues is a preferred target, and NO$_2$-FAs have been shown to modify the proteins, like Kelch-like ECH-associated protein 1, a repressor of the transcription factor Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (23), the signaling protein Peroxisome Proliferator-activated Receptor-γ (PPAR$γ$) (24), and NF-κB (19). In these selected cases, nitro-alkylation leads to modulation of downstream signaling events, resulting in changes in metabolic, inflammatory, and antioxidative pathways.

Here, we show that NO$_2$-FAs can be formed in response to viral infection. Furthermore, we show that NO$_2$-FAs can inhibit STING signaling and the release of type I IFNs in response to stimulation with the STING agonists, dsDNA and cGAMP, in addition to infection with the DNA virus HSV-2. Mechanistically,
NO₂-FAs directly modified STING through nitro-alkylation at the two adjacent cysteines at positions 88 and 91 (Cys88/91) and at an N-terminal histidine (His16), leading to a deregulation of STING palmitoylation and inhibition of STING signaling. Additionally, NO₂-FA treatment of immortalized fibroblasts from SAVI patients led to decreased STING-dependent type I IFN responses.

In conclusion, we show that endogenously formed NO₂-FAs are potent inhibitors of STING signaling and suggest that NO₂-FAs could be considered as a lipid-based treatment for STING-dependent inflammatory diseases.

Results

NO₂-FAs Are Formed in Response to Infection with Virus. As HSV infections are associated with release of high levels of reactive nitrogen species (25, 26), we tested if NO₂-FAs were formed in a model of vaginal HSV-2 infection, which induces a strong expression of iNOS (27). Expression of iNOS was most profoundly induced in leukocytes (CD45+ cells) at day 2 postinfection with HSV-2 (SI Appendix, Fig. S1); thus, plasma and vaginal lavages were collected at this time point. We found formation of the NO₂-FAs could be considered as a lipid-based treatment for STING-dependent inflammatory diseases.

NO₂-FAs Bind STING and Block STING Palmitoylation. Interestingly, we noticed a subtle but consistent mobility shift of STING monomers under nonreducing conditions (Fig. 2 E–G). This observation could implicate STING as an NO₂-FA target. To investigate this further, we treated with biotinylated forms of one NO₂-FA species, 10-NO₂-OA, and subsequently subjected to immunoprecipitations. Excitingly, biotinylated 10-NO₂-OA readily precipitated STING, indicating a possible direct modification of STING (Fig. 3A and B).

Encouraged by these results, human STING-transfected HEK293T cells were treated with 10-NO₂-OA. The precipitated and eluted STING protein was analyzed for NO₂-OA modifications by mass spectrometry. By this method, three sites of STING nitro-alkylation were identified: two adjacent cysteine residues at positions 88 and 91 in addition to a histidine residue at position 16 (Fig. 3 C and D). Common for all three sites is their location in close proximity to the predicted transmembrane helices of STING. Other than NO₂-OA, we observed NO-OA and NH₂-OA as additional modifications at cysteine residues due to reduction and laser desorption ionization, and we found one of the peptides partially and fully reduced and the other partially and nonreduced. None of these modified peptides were observed in the untreated sample (Fig. 3C). This observation is supported by experiments conducted with synthetic peptides. As previously described, no such reductions occurred at histidine residues. Additionally, we investigated the previously described modification of 200 Da (29), which confirmed our findings (SI Appendix, Figs S10 and S11).

In resting state, STING resides in the endoplasmic reticulum (ER) membrane, but binding to cGAMP initiates its translocation to Golgi membranes (30). Palmitoylation of STING at Cys88/91 recently has been shown to be essential for STING clustering in the TGN and for the downstream STING signaling (18). We, therefore, speculated if the underlying mechanism for NO₂-FA-mediated inhibition of STING palmitoylation could occur by preventing STING palmitoylation. For detection of palmitoylation, STINGKO mouse embryonic fibroblasts (MEF) expressing STING-Egfp were cultured in the presence of radio-labeled palmitate (¹⁴C-palmitate) before stimulation with the mouse STING agonist DMXAA. Using Gfp-specific antibodies, we precipitated STING and subsequently determined palmitoylation by measuring ¹⁴C-palmitate using an autoradiograph. As previously reported (18), treatment with DMXAA led to an increase in incorporation of ¹⁴C into STING (18). In contrast, pretreatment with 10-NO₂-OA, but not with OA, considerably inhibited this process (Fig. 3E). These results suggest that NO₂-FA–modified STING was unable to be palmitoylated after DMXAA stimulation. Since the palmitoylation of Cys88 and Cys91 of STING is stimulation dependent and likely occurs in the Golgi (18), Cys88 and Cys91 may be in the reduced form when STING is in the ER. We propose that treatment of cells with NO₂-FA before stimulation modifies Cys88 and Cys91 of STING through nitro-alkylation in the ER, preventing the normal palmitoylation process that occurs on these Cys residues at the
Golgi. Palmitoylation of STING is important for STING clustering at the TGN and for phosphorylation of TBK1 at this location (18). For detailed investigation, we used STING-KO MEFs expressing STING-EGFP and stimulated with DMXAA. Costaining for pTBK1 or TGN38 in the cell expressing STING-EGFP allowed us to test whether 10-NO₂-OA affected STING translocation to the TGN and/or phosphorylation of TBK1 by confocal microscopy. As expected, DMXAA stimulation induced translocation of STING to the perinuclear compartments, and STING colocalized with a TGN protein TGN38 (Fig. 3F, vehicle). pTBK1 signal showed up and partly colocalized with STING. On NO₂-FAs treatment, in ∼30% of the cells, the perinuclear translocation of STING was unaffected, whereas this was markedly reduced in the remaining ∼70% of cells (Fig. 3F, 10-NO₂-OA). Strikingly, phosphorylation of TBK1 was inhibited regardless of whether STING translocated to the TGN. OA treatment, as a vehicle treatment, did not affect the perinuclear translocation of STING and the emergence of phosphorylated TBK1 (Fig. 3F, OA). In summary, NO₂-FAs directly modify and nitroalkylate STING at Cys88 and Cys91, resulting in inhibited palmitoylation and leading to the suppression of phosphorylation of TBK1.

**NO₂-FAs Inhibit Release of Type I IFN in SAVI-Derived Fibroblasts.** Gain-of-function mutations in the gene encoding STING (TMEM173) have been shown to drive pathology through excessive release of type I IFNs in SAVI (4). Since NO₂-FAs have been reported to be a well-tolerated treatment in humans (clinicaltrials.gov: NCT02460146 and NCT02313064), we wanted to determine if NO₂-FAs could decrease type I IFN responses in three SAVI patient-derived fibroblast cell lines, all bearing the N154S mutation. Indeed, we observed that release of type I IFN in response to stimulation with dsDNA was greatly inhibited in all three patients on treatment with NO₂-FAs species (Fig. 4A–C). In line, the expression of IFN-β as well as the expression of the two IFN-stimulated genes (ISGs), IFIT1 and ISG15, were likewise suppressed with NO₂-FAs treatment (SI Appendix, Fig. S9). Furthermore, pTBK1, which was highly induced in the SAVI fibroblasts in response to cGAMP stimulation, was almost completely abolished by NO₂-FAs treatment (Fig. 4D). As basal IFN-β production in fibroblasts was below the detection limit (Fig. 4A–C), we used expression plasmids harboring gain-of-function STING mutants previously reported to cause SAVI (V174L, N154S, and V155M) to further test the treatment potential of NO₂-FAs. Indeed, NO₂-FAs treatment could dampen the STING-dependent release of type IFN in a ligand-independent manner in this setup. In summary, these results imply the therapeutic potential of NO₂-FAs by dampening type I IFN levels in SAVI patient fibroblasts.
Fig. 3. NO₂-FAs directly modify STING to inhibit palmitoylation. (A) THP-1 cells with endogenous STING and (B) HEK293T cells transfected with expression plasmid for human STING (Flag tagged) were treated with biotinylated 10-NO₂-OA (10 μM) or biotinylated OA (10 μM). After 1.5-h incubation, lysates were precipitated using mixed magnetic Streptavidin beads. Eluates and input samples were separated by SDS/PAGE, and STING (α-Flag) was detected by Western blotting. Blots represent representative results from two independent experiments. (C) HEK293T cells transfected with an expression plasmid for human STING were treated with 10-NO₂-OA (10 μM). After 1.5 h, STING was precipitated using STING-specific antibody and analyzed for nitro-alkylation by mass spectrometry. Graphics display (Left) an example spectrum of STING digest: Upper Left in black shows NO₂-OA–treated STING, and Lower Left in red shows untreated STING as a comparison. r.int (%), relative intensity in %. (Upper Right) List of matched peptides. (Lower Right) STING amino acid sequence with peptides containing nitro-alkylation marked in yellow. Data are displayed from a single experiment. (D) Graphic illustration of the positions of nitro-alkylated STING residues. (E) Immortalized STING-KO MEFs expressing GFP-tagged STING were treated with 10-NO₂-OA (10 μM), OA (10 μM), 2-bromopalmitate, 2-BP (50 μM), or vehicle control for 1 h. Cells were washed and incubated with radio-labeled palmitate (³H-palmitate) for 1 h before stimulation with DMXAA (25 mg/mL) or with vehicle control for an additional 1 h. Cells were lysed, and STING was precipitated (IP) using GFP-specific antibodies. Eluate and input were separated by SDS/PAGE and analyzed for contents of radio-labeled palmitate by autoradiography. STING was detected by immunoblotting, and α-tubulin was used as a loading control. Data displayed are from one of three independent experiments with same result. (F) Immortalized STING-KO MEFs expressing GFP-tagged STING were treated with 10-NO₂-OA (10 μM), OA (10 μM), or vehicle control as indicated before stimulation with DMXAA (25 mg/mL) or was left untreated (Ut) for 1 h. Cells that already express STING-GFP (green in merged panels) were fixed and stained for the TGN marker TGN38 (purple in merged panels) or pTBK1 (purple in merged panels), and the nuclei were stained with DAPI (blue in merged panels) and analyzed by confocal microscopy. The first three columns represent single stains of EGFP-STING, TGN38, and pTBK1, respectively. The last two columns represent merged images of EGFP-STING together with TGN38 and EGFP-STING together with pTBK1, respectively. Insets illustrate close-ups. Data represent two independent experiments.
Discussion

Gain-of-function mutations in STING can lead to a neonatal-onset systemic inflammatory condition characterized by severe cutaneous vasculopathy with extensive tissue loss and interstitial lung disease (SAVI) (4). Treatment options for SAVI patients or for patients with other STING-dependent inflammatory diseases are very limited. This is partly due to the absence of therapies that directly target STING signaling. This report identifies naturally occurring NO$_2$-FAs as potent inhibitors of STING signaling in human cells, including fibroblasts from SAVI patients. Thus, our data suggest that NO$_2$-FAs could be considered for trials aimed at treating patients with STING-dependent interferonopathies. This is further encouraged by the fact that NO$_2$-FAs are currently used in phase II trials for focal segmental glomerulosclerosis and pulmonary arterial hypertension and are here reported to be well-tolerated by the patients (clinicaltrials.gov: NCT02460146 and NCT02313064).

Our discovery that endogenous concentrations of NO$_2$-FAs are increased in response to virus-induced inflammation in mice together with the previous detection of NO$_2$-FA species and their adducts in human plasma and urine indicate that NO$_2$-FAs act as natural antiinflammatory mediators (31, 32). Testing this hypothesis is challenged by the difficulty to specifically eliminate NO$_2$-FAs from humans and even from mice. Antiinflammatory effects of the parent nonnitrated unsaturated lipids are widely reported (33). If part of these antiinflammatory effects is owing to the conversion into NO$_2$-FAs remains unknown. Notably, the parent nonnitrated unsaturated lipids have been documented to activate the PPAR$_\gamma$ pathway (34)—also a known NO$_2$-FA target (24). The idea that highly inflammatory NO-derived radicals, produced during inflammation, react with polyunsaturated lipids to form bioreactive antiinflammatory compounds is an attractive model for a built-in mechanism to counteract excessive inflammation. This hypothesis is supported by our demonstration that NO$_2$-FAs are formed in response to HSV-2 infection and in line with reported detection of NO$_2$-FAs formation in the peritoneum of mice after LPS injection (21, 35). Future research may focus on the importance of endogenous formation of NO$_2$-FAs to control inflammatory conditions in the context of either infection or noninfectious inflammatory disease.

Great advances have been made in understanding the structural basis for STING signaling in response to cytosolic dsDNA. Our data suggest that NO$_2$-FAs could be considered for trials aimed at treating patients with STING-dependent interferonopathies. This is further encouraged by the fact that NO$_2$-FAs are currently used in phase II trials for focal segmental glomerulosclerosis and pulmonary arterial hypertension and are here reported to be well-tolerated by the patients (clinicaltrials.gov: NCT02460146 and NCT02313064).
In conclusion, we have discovered that endogenously formed NO$_2$-FAs can target STING signaling and reduce release of type I IFNs in both murine and human cells—including fibroblasts from patients with the STING-dependent interferonopathy SAVI. We, therefore, suggest that these lipids can be considered in the treatment of STING-dependent inflammatory diseases.

Materials and Methods

Animals. Animals received proper care in agreement with animal protocols approved by Animal Welfare Bodies at Health, Aarhus University, and we performed vaginal HSV-2 infection with ethical permission from the Animal Experiments Inspectorate, Danish Veterinary and Food Administration. Full details can be found in SI Appendix, SI Materials and Methods.

Cell Lines and Cell Culture. Full details can be found in SI Appendix, SI Materials and Methods.

Viruses and Reagents. Full details can be found in SI Appendix, SI Materials and Methods.

Vaginal HSV-2 Infection. Full details can be found in SI Appendix, SI Materials and Methods.

Analytical Determination of NO$_2$-FAs Levels. Full details can be found in SI Appendix, SI Materials and Methods.

Cell Stimulation Setups. For in vitro HSV-2 stimulation, multiplicity of infection (MOI) at 0.5 or 1 was used. For transfection setups, 4 μg/mL dsDNA (HSV-60; InvivoGen) and 4 μg/mL Lipofectamine2000 (Invitrogen) were used according to the manufacturer’s instructions. Furthermore, cGAMP (Invitrogen) was used at a concentration of 4 μg/mL together 4 μg/mL Lipofectamine2000. Stimulation with cGAMP was performed using 4 μg/mL delivered to cells using Lipofectamine2000 (Invitrogen).

Functional Type I IFN Assays. Murine IFN-α/β bioactivity was measured by an L929 cell-based bioassay as previously described (36). Human type I IFN bioactivity was quantified using the reporter cell line HEK-Blue IFN-α/β, according to the manufacturer’s instructions. SEAP levels were assessed by measuring OD at 620 nm on a microplate reader (ELx808; BioTek).

Immunoprecipitation. Cells were lysed in Pierce RIPA lysing buffer (ThermoFisher Scientific) supplemented with 1× complete protease mixture inhibitor (Roche) and 5 μM 5′-benzamide (Sigma). Lysate was collected and incubated with Pierce Streptavidin magnetic beads (ThermoFisher Scientific) for pulldowns experiments of biotinylated NO$_2$-FAs. Samples were washed once in PBS supplemented with 0.05% Tween-20, once with lysis buffer, and four times in 1 M KCl. Samples were eluted in 1× XT Sample Buffer (BioRad) and 1× XT reducing agent (BioRad) and further processed as described in Immunoblotting. Dynabeads Protein G (Invitrogen) was used for elution of STING for mass spectrometry analysis.

Detection of Nitro-Alkylation by Mass Spectrometry. Full details can be found in SI Appendix, SI Materials and Methods.

Metabolic Labeling with [3H]-Palmitate. Full details can be found in SI Appendix, SI Materials and Methods.

Immunocytochemistry and Confocal Microscopy. They were previously described in ref. 18.

Luciferase Assay. For ARE-Luciferase assays, experiments were performed as previously described using the calcium phosphate transfection method. After 24 h of transfection and stimulation, luciferase activity was measured with a dual-luciferase reporter assay and a GloMax 20/20 luminometer as previously reported (37).

Immunoblotting. Full details can be found in SI Appendix, SI Material and Methods.

Primary Fibroblast Cell Lines Derived from SAVI Patients’ Superficial Skin Biopsies. Patients with genetically confirmed SAVI were enrolled into the protocol (clinicaltrials.gov: NCT02974595) at the NIH between 2008 and 2015. The protocol was approved by the National Institute of Allergy and Infectious Diseases IRB at the NIH. Written informed consent was obtained from all participating patients or their legal guardians (R.G.-M.). Superficial research biopsies were obtained, and primary fibroblast cell lines were generated (4).

Acknowledgments. We thank Soren R. Paludan for reagents used in this study. A.L.H. is supported by C. C. Klesstrup and Wife Henriette Klesstrup’s Foundation, Director Jacob Madsen and Wife Olga Madsen’s Foundation, The Bohemian Foundation, and Lily Benthine Lund’s Foundation of 1.6.1978 in addition to a PhD fellowship from the Department of Health Sciences at Aarhus University. K.M. is supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant JP17K15445 and ONO Medical Research Foundation. M.B.I. is supported by a Lundbeck postdoctoral fellowship. H.A. is supported by JSPS KAKENHI Grants JP17H06164 and JP17H06418, and AMED-CREST Grant 15652285. T.T. is supported by JSPS KAKENHI Grants JP16H04782 and JP15H05903 and AMED-PRIME. F.J.S. is supported by NIH Grants R01-GM125944 and R01-DK112854 and American Heart Association Grant 17GRN33660955. D.O. is supported by a Carlsbergfonden International Research Fellowship. C.K.H. is supported by The Hørslev Foundation, and Hans Sørensen’s Foundation, The Augustinus Foundation, and Hede Nielsen’s Foundation.